Harrison.ai vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 54)
Harrison.ai logo

Harrison.ai

ChallengerHealthcare

AI-Powered Clinical Diagnostics (Radiology & Pathology)

Harrison.ai is an Australian healthcare AI company building clinical-grade AI for radiology and pathology diagnostics; raised $129M+ AUD total at a $400M AUD valuation; its Annalise.ai radiology platform has FDA clearance and processes 5M+ studies;

AI VisibilityBeta
Overall Score
C54
Category Rank
#176 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
53
Gemini
50

About

Harrison.ai is a Sydney, Australia-based healthcare artificial intelligence company founded in 2018 by brothers Aengus and David Hallinan that builds clinical-grade AI models for diagnostic medicine, initially targeting radiology and pathology. The company''s flagship product — Annalise.ai — is a comprehensive AI platform for radiology interpretation that analyzes chest X-rays, CT scans, and other medical imaging studies to detect and flag a broad range of findings simultaneously. Unlike earlier radiology AI tools designed for single conditions, Annalise.ai is a multi-finding model trained to detect up to 124 findings in a single chest X-ray and 295 findings in chest CTs — providing a comprehensive AI second reader experience rather than a narrow single-disease detector.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

54
Overall Score
93
#176
Category Rank
#1
85
AI Consensus
80
stable
Trend
stable
52
ChatGPT
94
53
Perplexity
89
50
Gemini
94
55
Claude
92
49
Grok
98

Key Details

Category
AI-Powered Clinical Diagnostics (Radiology & Pathology)
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.